Capital Research Global Investors Sells 6,665 Shares of Establishment Labs Holdings Inc. $ESTA

Capital Research Global Investors decreased its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 807,826 shares of the company’s stock after selling 6,665 shares during the period. Capital Research Global Investors owned approximately 2.78% of Establishment Labs worth $58,874,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. increased its position in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after acquiring an additional 438,206 shares during the last quarter. BNP Paribas Financial Markets increased its position in Establishment Labs by 296.8% during the fourth quarter. BNP Paribas Financial Markets now owns 196,120 shares of the company’s stock valued at $14,293,000 after acquiring an additional 146,697 shares during the last quarter. Geode Capital Management LLC increased its position in Establishment Labs by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 28,070 shares of the company’s stock valued at $2,043,000 after acquiring an additional 2,157 shares during the last quarter. Royce & Associates LP increased its position in Establishment Labs by 24.2% during the fourth quarter. Royce & Associates LP now owns 358,541 shares of the company’s stock valued at $26,130,000 after acquiring an additional 69,766 shares during the last quarter. Finally, Simplify Asset Management Inc. increased its position in Establishment Labs by 92.1% during the fourth quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock valued at $5,313,000 after acquiring an additional 34,946 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 330,000 shares of company stock worth $22,854,538 over the last ninety days. 9.99% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Canaccord Genuity Group boosted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. BTIG Research boosted their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Stephens boosted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Mizuho boosted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Stock Up 6.7%

Shares of ESTA opened at $79.82 on Wednesday. The firm has a market capitalization of $2.35 billion, a P/E ratio of -53.57 and a beta of 1.11. Establishment Labs Holdings Inc. has a 12-month low of $33.35 and a 12-month high of $83.31. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm has a fifty day moving average price of $67.28 and a 200-day moving average price of $68.87.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) earnings per share. Equities research analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.